EVM
CTSO icon

Eaton Vance Management’s Cytosorbents Corp CTSO Stock Holding History

Eaton Vance Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-807
Closed -$3K – 1991
2021
Q4 		$3K Sell
807
-220
-21% -$1.23K ﹤0.01% 2692
2021
Q3 		$0 Buy
1,027
+102
+11% +$829 ﹤0.01% 2147
2021
Q2 		$7K Buy
+925
New +$7.79K ﹤0.01% 2591

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Eaton Vance Management's CTSO Position: Q1 2022 in Review

Eaton Vance Management sold out of Cytosorbents Corp (CTSO) in Q1 2022, closing a stake of 807 shares — an estimated $3K sold.

Eaton Vance Management first reported a position in CTSO in Q2 2021 and held it in 3 quarters. The position peaked at $7K in Q2 2021. 88 funds tracked by Wall St. Rank hold CTSO as of Q1 2022.

  • Eaton Vance Management reported no remaining Cytosorbents Corp position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 807 Cytosorbents Corp shares in Q1 2022, an estimated $3K.
  • Eaton Vance Management first reported a position in Cytosorbents Corp in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Cytosorbents Corp position peaked at $7K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.